ErbB4 _ HER4 Protein
- Known as:
- ErbB4 _ HER4 Protein
- Catalog number:
- 10363-H03H
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- ErbB4 _ HER4 Protein
Related genes to: ErbB4 _ HER4 Protein
- Gene:
- ERBB4 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 4
- Previous symbol:
- -
- Synonyms:
- ALS19, HER4
- Chromosome:
- 2q34
- Locus Type:
- gene with protein product
- Date approved:
- 1995-09-07
- Date modifiied:
- 2016-10-05
Related products to: ErbB4 _ HER4 Protein
Related articles to: ErbB4 _ HER4 Protein
- Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder in reproductive-age women, characterized by limited therapeutic options that address its underlying mechanisms. This study aimed to identify novel druggable protein targets for PCOS using a multi-omics integrative approach. Proteome-wide association studies (PWAS)-Mendelian randomization (MR) and summary-based MR (SMR) analyses were performed on large-scale plasma proteomics data from deCODE and UK Biobank cohorts, integrated with PCOS genome-wide association study (GWAS) summary statistics to screen for causal associations. Validation and prioritization involved Bayesian colocalization, transcriptome-wide association studies (TWAS), methylome-wide association studies (MWAS), and Gene Expression Omnibus (GEO) differential expression analysis. Biological mechanisms, druggability, and potential side effects were evaluated through protein-protein interaction networks, Gene Ontology/Kyoto Encyclopedia of Genes and Genomes enrichment, single-cell expression profiling, drug prediction via DSigDB, molecular docking, and MR-phenome-wide association studies (PheWAS). Fifty-seven candidate proteins were nominally associated with PCOS risk. FSHB met the stringent high-colocalization criterion (PPH4 > 0.8), whereas THOP1, CAMKK1, PDLIM4, and ERBB4 met the broader colocalization criterion (PPH3 + PPH4 > 0.8). After robustness filtering, ERBB4 was retained as a secondary candidate, and THOP1, FSHB, CAMKK1, and PDLIM4 were prioritized as tier 1 targets, with pathway analyses implicating lysosomal and MAPK-related processes. Drug predictions identified compounds such as Triciribine and 1,3,5(10)-Estratriene-2,3-diol-17-one, demonstrating favorable docking affinities (e.g., - 9.7 kcal/mol for FSHB). MR-PheWAS indicated limited side effects for most targets, except for FSHB-associated reproductive risks. These findings offer robust evidence for prioritized therapeutic targets, facilitating advancements in precision medicine and drug development for PCOS. - Source: PubMed
Publication date: 2026/05/22
Xiao ZhiyongZhang XinZhang YuxinLiu JiajiaZheng XiaoyanLai RuiYang HanWu JieYang Jie - Thoracolumbar compression fractures are common in older adults. Percutaneous kyphoplasty (PKP) is a standard minimally invasive treatment, but 30% to 50% of patients still have persistent or inadequate pain relief after the procedure. - Source: PubMed
Publication date: 2026/05/21
Fang MinWang JuanZhu YongliangZhao Hui - Wilms tumor presents a heterogeneous tumor microenvironment. This study aimed to characterize the tumor microenvironment and identify prognostic genes to improve therapeutic strategies. - Source: PubMed
Publication date: 2026/05/20
Gao ZhiqiangLin JieTang HuafeiLi AoLi RuiXu AoHu RuiXu ShuaiZhang MaolinYang WenmingHuang HaijingZhang ZhengLiu Feng - Coronary microvascular dysfunction (CMD) participates in the pathophysiology of multiple cardiovascular diseases, but treatment options are limited. A new treatment option may include ERBB4 stimulation by neuregulin-1 (NRG1), which has anti-inflammatory, antifibrotic, and cardioprotective effects in models of heart failure. To assess the effect NRG1/ERBB4 stimulation on CMD in hypertensive heart disease. Hypertensive heart disease was induced in 12 Aachener minipigs by implantation of deoxycorticosterone acetate (DOCA) pellets for 8 weeks and compared to 6 controls. The DOCA pigs were randomized to a weekly infusion of JK07, a NRG1 fusion protein with improved pharmacokinetic and pharmacodynamic properties, or vehicle. Microvascular resistance was measured using the bolus thermodilution method. DOCA significantly increased microvascular resistance compared to controls (from 14.5 to 19.9 mmHg.s, p = 0.028). This increase was abrogated by JK07 (11.3 mmHg.s, p = 0.018 vs DOCA). dP/dtmax increased by DOCA compared to controls (from 2415.5 to 4455.5 mmHg/s, p = 0.011), which was also abrogated by JK07 (3107.3 mmHg/s, p = 0.055 vs DOCA). Interstitial left ventricular fibrosis was significantly lower in JK07-treated pigs compared to DOCA only (2.1 vs. 5.4 %, p = 0.026), but without difference in perivascular fibrosis (p = 0.48). JK07 did not affect myocyte cross-sectional area, capillary density, pericyte coverage, microvascular vessel thickness, inflammatory cytokines, or endothelial activation. ERBB4 activation by JK07 can prevent CMD in a DOCA hypertensive pig model. The exact mechanism of the protective effects of JK07 on microvascular resistance remains elusive however. - Source: PubMed
Publication date: 2026/05/19
Tubeeckx Michiel RlBringmans TijsGoovaerts BoVan den Bogaert SielGrootaert Mandy OjJones Elisabeth AvKorpisalo PetraJuusola GretaWirth GalinaMurphy Samuel LHeidbuchel HeinDe Keulenaer Gilles WSegers Vincent Fm - Epilepsy is a complex central nervous system disease with a high incidence and a significant social health burden. Although there are many antiepileptic drugs, about 30% of patients are insensitive to existing drug treatments, and it is urgently required to identify reliable molecular markers and therapeutic targets. Traditional research has focused on a single omics level, and it is difficult to establish a complete connection from genetic variation to changes in cell function. In this study, a multi-level analysis framework integrating transcriptome, proteome, Mendelian randomization, and single-cell omics was constructed, and the E3 ubiquitin ligase RNF149 was systematically screened and multi-dimensionally verified as a key candidate molecular marker for epilepsy. In external datasets (GSE88992, GSE127871, GSE255223) and animal models, RNF149 showed a stable trend of differential expression and was associated with hippocampal sclerosis and the severity of epileptic seizures. Single-cell communication investigation revealed that RNF149 may influence the pathological process of epilepsy by modulating the interaction between excitatory neurons and oligodendrocytes, particularly the NRG3-ERBB4 signaling axis. In conclusion, multi-omics integrated analysis highlighted RNF149's potential relevance as a molecular biomarker and treatment target for epilepsy, generating new ideas for precision diagnosis and mechanism research in temporal lobe epilepsy. - Source: PubMed
Publication date: 2026/05/09
Wei BiQian XuehongMao RunningYu KaiWang YusenChen HongbingXiong HongliLi Jianbo